IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …
[HTML][HTML] Glioblastoma targeted therapy: updated approaches from recent biological insights
Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …
representing a highly heterogeneous group of neoplasms that are among the most …
[HTML][HTML] A vaccine targeting mutant IDH1 in newly diagnosed glioma
Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Abstract The oncometabolite (R)-2-hydroxyglutarate (R-2-HG) produced by isocitrate
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …
dehydrogenase (IDH) mutations promotes gliomagenesis via DNA and histone methylation …
[HTML][HTML] IDH mutations in cancer and progress toward development of targeted therapeutics
L Dang, K Yen, EC Attar - Annals of Oncology, 2016 - Elsevier
ABSTRACT Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes,
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …
[HTML][HTML] Biological role and therapeutic potential of IDH mutations in cancer
Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …
Advances in neuro-oncology imaging
KJ Langen, N Galldiks, E Hattingen… - Nature Reviews …, 2017 - nature.com
Despite the fact that MRI has evolved to become the standard method for diagnosis and
monitoring of patients with brain tumours, conventional MRI sequences have two key …
monitoring of patients with brain tumours, conventional MRI sequences have two key …
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15
months despite an aggressive standard of care that includes surgery, chemotherapy, and …
months despite an aggressive standard of care that includes surgery, chemotherapy, and …
The roles of 2-hydroxyglutarate
X Du, H Hu - Frontiers in Cell and Developmental Biology, 2021 - frontiersin.org
2-Hydroxyglutarate (2-HG) is structurally similar to α-ketoglutarate (α-KG), which is an
intermediate product of the tricarboxylic acid (TCA) cycle; it can be generated by reducing …
intermediate product of the tricarboxylic acid (TCA) cycle; it can be generated by reducing …
Isocitrate dehydrogenase mutations in gliomas
Over the last decade, extraordinary progress has been made in elucidating the underlying
genetic causes of gliomas. In 2008, our understanding of glioma genetics was …
genetic causes of gliomas. In 2008, our understanding of glioma genetics was …